Evaluation of creams and ointments as suitable formulations for peldesine

International Journal of Pharmaceutics

Volumn 219, Issue 1-2, 2001, Pages 73-80

  Viegas, Tacey X ^a   Van Winkle, Lise L ^a   Lehman, Paul A ^b   Franz, Sue F ^b   Franz, Thomas J ^c  

^a BIOCRYST PHARMACEUTICALS INC   (United States)

^b DermTech International   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

BCX 34; Dermal formulations; In vitro skin delivery; Peldesine; Penetration enhancers; Purine nucleoside inhibitor

Indexed keywords

BUFFER; CAPRIC CAPRYLIC ESTER DERIVATIVE; EMEREST 2314; EMERSOL 221; ESTER DERIVATIVE; GLYCEROL; LANOLIN; LANOLIN ALCOHOL; MIGLYOL; MYRISTIC ACID ISOPROPYL ESTER; OLEIC ACID; OPTIM; PELDESINE; PETROLATUM; PHOSPHATE; PROPYLENE GLYCOL; SOFTISAN 378; UNCLASSIFIED DRUG; WHITE PROTOPET;

ARTICLE; CADAVER; CONTROLLED STUDY; CREAM; CRYOPRESERVATION; DERMIS; DIFFUSION CHAMBER; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG LABELING; DRUG SOLUBILITY; DRUG STRUCTURE; EPIDERMIS; HUMAN; HUMAN TISSUE; HYDROPHOBICITY; OINTMENT; PH; PRIORITY JOURNAL; SCINTILLATION SPECTROMETRY;

ALGORITHMS; CAPRYLATES; DERMATOLOGIC AGENTS; DIFFUSION; EMULSIONS; EXCIPIENTS; GUANINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYRISTATES; OINTMENT BASES; OINTMENTS; PROPYLENE GLYCOLS; SKIN ABSORPTION; SOLUBILITY;

EID: 0035927203     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(01)00632-9     Document Type: Article

References (16)

1. In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: The role of GTP and dGTP
2. Methods for in-vitro percutaneous absorption studies. III. Preparation of barrier layer
3. Chapter 20: General introduction and conceptual differentiation of topical and transdermal drug delivery systems
4. Membrane diffusion III: Influence of solvent composition and permeant solubility on membrane transport
5. The finite dose technique as a valid model for the study of percutaneous absorption in man
6. The use of water permeability as a means of validation of skin integrity in in-vitro percutaneous absorption studies
7. Quantitative determination of peldesine, a PNP inhibitor, by spectrophotometry and high performance liquid chomatography
8. Chapter 53: Dermatopharmacokinetics of topical BCX-34 cream in human skin
9. Chapter 18: Semisolids
10. Formulation factors affecting release of drug from topical formulations. I. Effect of emulsion type upon in-vitro delivery of ethyl p-aminobenzoate
11. Formulation factors affecting release of drug from topical formulations. II. Effect of solubility on in-vitro delivery of a series of n-alkyl p-aminobenzoates
12. Purine nucleoside phosphorylase deficiency
13. Chapter 6: In vivo relationship between percutaneous absorption and transepidermal water loss
14. Application of kinetic model to in vitro percutaneous permeation of drugs
15. Solubilization by cosolvents II: Phenytoin in binary and ternary solvents
16. Preformulation studies for the development of a parenteral liquid formulation of the immunomodulator, peldesine